Project description
Novel therapeutic targets against colorectal cancer
Immune system activation constitutes a promising approach for the treatment of cancer. However, it has not been possible to identify cancer-specific targets for therapeutic and diagnostic purposes. The EU-funded InnoTACA project aims to identify tumour-associated carbohydrate antigens (TACA) in colorectal cancer (CRC), which currently has limited treatment options. Researchers envision the identification of molecules that will serve as leads for the development of safer and more cost-effective immunotherapies applicable to even advanced unresectable CRC. Moreover, these targets can be used to predict the clinical outcome during cancer management and treatment.
Objective
CellmAbs is a recent but fast growing biopharmaceutical spinoff dedicated to the development of immuno-oncology agents that target only cancer cells, promoting the activation of the immune system and inhibiting growth of cancer in both early and late stages.
In spite of many advances in diagnostic and treatment development, many cancers still have no targeted therapy or have limited or toxic treatment options. Early detection is crucial to optimize treatment and substantially reduce incidence and mortality. In spite of the advent of new and improved genomic and proteomic technologies, it has not been possible to identify cancer-specific therapeutic targets or molecules that are able to reliably and accurately predict outcomes during cancer management and treatment. Cancers such as colorectal cancer (CRC) have very poor standard of care and thus own an unmet need for reliable and specific targets. The discovery of tumour associate carbohydrate antigens (TACA) is very promising but is still very insipient due to lack of experts, knowledge and technology on the field.
InnoTACA will address several unmet needs by presenting the grounds for hiring an Innovation Associate with relevant expertise and experience on groundbreaking technology to innovate TACA discovery to apply in cancer theranostic, combining high-quality transferable-skill training with excellent scientific training in glycomics. InnoTACA addresses the CellmAbs need of identifying highly specific TACAs, which would serve as a lead for the development of safer and more cost-effective immunotherapies, even for advanced unresectable CRC.
The InnoTACA Associate and such immunotherapies will provide CellmAbs with improved products to capitalize and compete with current healthcare business and it will allow CellmAbs to connect with other high-tech SMEs focused in pharmaceutical and medical development, and partners with strong translational clinical and research backgrounds.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- social sciencessociologydemographymortality
- medical and health sciencesclinical medicineoncologycolorectal cancer
- natural sciencesbiological sciencesbiochemistrybiomoleculescarbohydrates
- medical and health sciencesbasic medicineimmunologyimmunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Programme(s)
Call for proposal
(opens in new window) H2020-INNOSUP-2018-2020
See other projects for this callSub call
H2020-INNOSUP-2020-02
Funding Scheme
CSA - Coordination and support actionCoordinator
2510-216 Leiria
Portugal
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.